Avacta Group PLC Fundamentals Datasheet and Stock Analysis

Profile

Avacta Group PLC Company Logo
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

  • Current Price:
     29.50p
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
     GB00BYYW9G87
  • Market Sector:
     AIM
  • Main Indices:
     FTSE AIM
  • Country of register:
     Great Britain
  • Currency:
     N/A
  • Shares in Issue:
     69m
  • Market Cap:
     £931m
  • Date Listed:
     26/01/2016
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)

Loading...

Activity Data Not Available

Company Information

CEO: Alastair Smith  CFO: Tony Peter Gardiner  Non-Executive Director: Mike Owen Alan John Aubrey  Non-Executive Chairman: Trevor Nicholls  

  • Registrars:
     Capita Registrars
  • Address:
     Unit 20, Ash Way, Thorp Arch Estate, Wetherby, United Kingdom
  • Phone:
     +44 (0)84 4414 0452
  • Website:
     http://www.avacta.com
Analysis
Composite Ranking: 27
Historic EPS Ranking: 63
Forecast EPS Ranking: 25
Price Relative Strength: 2
Industry Strength: E
SMR Ranking: 
ROCE Ranking: F
Accumulation/Dist: 
Mkt Accumulation/Dist: C
Unbroken Annual EPS: E
Unbroken Interim EPS: E
PEG Current Ranking: A
PEG Forecast Ranking: A
PE Current Ranking: A
PE Forecast Ranking: A
Margin Current Ranking: H
Margin Forecast Ranking: H
Chart
Add Indicator




loading




Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Fundamentals
20112012201320142015201620172018E2019E
Day/Month31/731/731/731/731/731/731/731/731/7
Revenue£m2.443.132.701.621.812.172.73£m3.123.57
Operating Profit/(loss)£m(1.13)(1.64)(1.87)(2.05)(5.57)(5.66)(7.98)£m0.000.00
Profit Before Tax£m(1.12)(1.60)(1.85)(2.02)(5.54)(5.57)(7.89)£m(9.23)(10.29)
Profit After Tax£m(0.59)(1.11)(1.52)(1.47)(4.89)(4.65)(6.37)£m0.000.00
Profit After Tax (from discontinued operations)£m0.000.000.00(0.02)(5.10)0.000.00£m0.000.00
Overall Profit for the Period£m(0.59)(1.11)(1.52)(1.49)(9.99)(4.65)(6.37)£m0.000.00
EPS Growth%0.000.000.000.000.000.000.00%0.000.00
Earnings Per Sharep(4.00)(4.00)(5.00)(4.00)(10.00)(6.86)(9.31)p(11.59)(12.71)
Op. Cash Flow P/Sp(0.04)(0.01)0.000.000.000.000.00£0.000.00
Cash Flow P/S Grth%0.000.000.000.000.000.000.00%0.000.00
Net Cash Flow P/Sp0.110.000.000.000.000.000.00£0.000.00
Capital Exp P/S£0.000.000.000.000.000.000.00£0.000.00
Tax Rate%47.330.000.000.000.000.000.00%0.000.00
P/E Ratiox0.000.000.000.000.000.000.00x0.000.00
P/E Growth£0.000.000.000.000.000.000.00£0.000.00
Turnover Per Share£0.160.060.000.000.000.000.00£0.000.00
Pre-Tax Profit / Share£(0.07)(0.03)0.000.000.000.000.00£0.000.00
Operating Margin%(46.01)0.00(69.37)(126.39)(307.73)(260.83)(292.31)%0.000.00
ROCE%0.000.00(191.12)(16.11)(63.17)(22.85)(44.86)%0.000.00
ROE%(5.16)0.000.000.000.000.000.00%0.000.00
Mkt Cap£m1,708.2051.9858.3073.1397.9758.3055.88£m0.000.00
Dividend Per Sharep0.000.000.000.000.000.000.00p0.000.00
DPS Growth%0.000.000.000.000.000.000.00%0.000.00
Dividend Yield%0.000.000.000.000.000.000.00%0.000.00
Dividend Coverx0.000.000.000.000.000.000.00x0.000.00
Shareholder Funds£m11.4416.9615.5528.8419.1335.8629.89£m0.000.00
Net Borrowings£m(1.77)(4.19)(0.58)(11.48)(7.33)(9.52)(9.17)£m0.000.00
Net Assets£m11.4416.9615.5528.8419.1335.8629.89£m0.000.00
Net Assets P/S£0.140.000.000.000.000.000.00£0.000.00
Financials
Latest Forecast
Div Yield0.0%0.0%
Div Cover0.0%0.0%
Op Margin-292.3%-296.0%
ROCE0.0%
Director Deals
Traded Action Notifier Price Amount Value
09-Apr-18BuyMichael Scott Albin36.25p 10,345£3,750.06
13-Mar-18BuyAlastair Smith41.92p 35,800£15,007.36
04-Jan-18BuyMichael Scott Albin64.60p 5,805£3,750.03
10-Sep-17BuyMichael Scott Albin70.60p 5,311£3,749.57
21-Aug-17BuyAlastair Smith74.50p 33,225£24,752.63
04-Jul-17BuyMichael Scott Albin86.30p 4,345£3,749.73
06-Apr-17BuyMichael Scott Albin61.80p 5,731£3,541.76
21-Oct-16BuyMike Owen90.00p 7,763£6,986.70
07-Jul-16BuyMichael Scott Albin92.10p 3,393£3,124.95
29-Apr-16BuyCraig Slater1.13p2,222£2,499.75
First PagePrev PageNext Page  Rows per page
Shareholders
69m    Major: 67%    Director: 1%
Notifier Holding Value
Alastair Smith606,309£178,861.16
Alan John Aubrey191,334£56,443.53
Trevor Nicholls35,000£10,325
Mike Owen7,763£2,290.08
  Rows per page
Gearing & Cover
News
News Title Date Time Source
Holding(s) in Company30-Apr-1816:45RNS
Interim Results16-Apr-1807:25RNS
Issue of Equity09-Apr-1814:58RNS
Directorate Change29-Mar-1807:00RNS
Avacta to Present at Investor Forum29-Mar-1807:00RNS-R
Director/PDMR Shareholding13-Mar-1812:02RNS
Price Monitoring Extension07-Mar-1816:35RNS
Summary of Capital Markets Day08-Feb-1807:00RNS-R
Avacta and OncoSec to Collaborate22-Jan-1807:00RNS
Result of Annual General Meeting18-Jan-1811:26RNS
First PagePrev PageNext Page  Rows per page
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change
18-May-15Numis SecuritiesBuy1.05p1.50p1.70pReiteration
12-Feb-15Panmure GordonBuy0.77p1.75p1.75pReiteration
09-Aug-11Merchant SecuritiesBuy0.81p1.00p0.00pReiteration
  Rows per page
Notes

This functionality requires you to login

Click here to login
Or register for a new account